Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Abecassis

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Journal of Hepatology|December 15, 2010
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlationAhsun Riaz, Khairuddin Memon, Frank H Miller, et al.
Transplantation|April 24, 2015
Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein ThrombosisRiad Salem, Michael Vouche, Talia Baker, et al.
Kidney International Reports|December 23, 2017
Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney TransplantationIlaria Gandolfini, Cynthia Harris, Michael Abecassis, et al.
Annals of Surgery|August 11, 2015
Defining long-term outcomes with living donor liver transplantation in North AmericaKim M Olthoff, Abigail R Smith, Michael Abecassis, et al.
Gastroenterology|June 14, 2011
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival timesKhairuddin Memon, Laura Kulik, Robert J Lewandowski, et al.
Journal of the American Society of Nephrology : JASN|June 7, 2015
Urine Metabolite Profiles Predictive of Human Kidney Allograft StatusKarsten Suhre, Joseph E Schwartz, Vijay K Sharma, et al.
The New England Journal of Medicine|July 5, 2013
Urinary-cell mRNA profile and acute cellular rejection in kidney allograftsManikkam Suthanthiran, Joseph E Schwartz, Ruchuang Ding, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experienceRiad Salem, Ahmed Gabr, Ahsun Riaz, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 19, 2011
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis CGöran B Klintmalm, Gary L Davis, Lewis Teperman, et al.
Transplantation|February 17, 2017
Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in DirectionPhilip J OʼConnell, Dirk R Kuypers, Roslyn B Mannon, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Journal of Hepatology|December 15, 2010
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlationAhsun Riaz, Khairuddin Memon, Frank H Miller, et al.
Transplantation|April 24, 2015
Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein ThrombosisRiad Salem, Michael Vouche, Talia Baker, et al.
Kidney International Reports|December 23, 2017
Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney TransplantationIlaria Gandolfini, Cynthia Harris, Michael Abecassis, et al.
Annals of Surgery|August 11, 2015
Defining long-term outcomes with living donor liver transplantation in North AmericaKim M Olthoff, Abigail R Smith, Michael Abecassis, et al.
Gastroenterology|June 14, 2011
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival timesKhairuddin Memon, Laura Kulik, Robert J Lewandowski, et al.
Journal of the American Society of Nephrology : JASN|June 7, 2015
Urine Metabolite Profiles Predictive of Human Kidney Allograft StatusKarsten Suhre, Joseph E Schwartz, Vijay K Sharma, et al.
The New England Journal of Medicine|July 5, 2013
Urinary-cell mRNA profile and acute cellular rejection in kidney allograftsManikkam Suthanthiran, Joseph E Schwartz, Ruchuang Ding, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experienceRiad Salem, Ahmed Gabr, Ahsun Riaz, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 19, 2011
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis CGöran B Klintmalm, Gary L Davis, Lewis Teperman, et al.
Transplantation|February 17, 2017
Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in DirectionPhilip J OʼConnell, Dirk R Kuypers, Roslyn B Mannon, et al.
Pageof 12